Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

JEFFREY A PASSER

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1326057571
CMS profile
600013
Location
OMAHA, NE

General Payments · PY2018–2024

$118,246.55

  • Reported across 292 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$30,367.50

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $30,367.50 13

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $30,367.50 13

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $905.33 66
PY2019 $1,031.23 72
PY2020 $9,243.38 45
PY2021 $25,930.26 68
PY2022 $31,312.50 19
PY2023 $19,456.35 9
PY2024 $30,367.50 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 1137649156 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 1137649158 CMS
Takeda Pharmaceuticals U.S.A., Inc. $607.50 02/26/2024 Consulting Fee Undisputed 01/23/2026 1137649160 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 1137649162 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 1137649164 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 1137649166 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,430.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 1137649168 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 1137649170 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1137649172 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 1137649174 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 1137649176 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 1137649178 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,530.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 1137649180 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.